BLOG/🇮🇳India··daily

India Startup Funding Venture Capital Filings — March 30, 2026

India Startup Funding

9 medium priority9 total filings analysed

Executive Summary

Across 9 filings in the India Startup Funding stream, a dominant theme is corporate investments and stake acquisitions targeting healthcare, renewables, finance, snacks, and manufacturing startups/subsidiaries, with total commitments exceeding ₹1,300 Crore including HCG's ₹253.66 Crore and Aequs' ₹90+ Crore infusions. Period-over-period trends reveal mixed revenue performance: strong YoY growth in HCG NCHRI (39.7% FY24, 25.1% FY25) and FETN1PL (353% FY24) contrasts with declines in Vizag Hospital (-8.4% FY25), AEPPL (turnover -49% FY25 vs FY24), and ACPPL (-49% FY25). Neutral-to-mixed sentiments prevail due to growth pockets amid recent slowdowns, with no major insider selling but promoter reshuffles and new stake intents signaling conviction. Capital allocation leans toward subsidiary funding via rights issues/IPO proceeds, highlighting reinvestment over dividends. Key implications include potential undervalued entry points in distressed investees and watch for open offers/captives boosting energy independence. Portfolio-level, 4/9 filings show revenue deceleration QoQ/YOY, flagging sector maturation risks but alpha in healthcare/renewables outliers.

Tracking the trend? Catch up on the prior India Startup Funding Venture Capital Filings digest from March 26, 2026.

Investment Signals(12)

  • HCG NCHRI revenue +39.7% YoY FY24 to ₹71.78 Cr, +25.1% FY25 to ₹89.80 Cr with PAT ₹17.02 Cr; investing ₹98 Cr + ₹155.66 Cr for 85% Vizag stake

  • FETN1PL turnover +353% YoY FY24 to ₹845.27 Lakhs; Magna invests ₹39.6 Lakhs for 7.83% stake to secure 1.1 MWp captive solar under Electricity Act

  • Promoter group (Ajinkya + Sundaram) acquired 13.42% (50.54L shares) at ₹358.20/share (discounted vs 60-day VWAP ₹395.55), aggregate holding stable at 74.13%

  • Allotted 9.29 Cr shares + 9.29 Cr warrants at ₹236 to BC Asia PACs, post-issue 9.89% (18% FD), signaling strong investor commitment

  • Leading Leasing net acquired 0.37% (9.48L shares) via open market on Mar 27, 2026, stake up to 11.72%

  • Authum intends >5% acquisition per Reg 29(2), potential strategic entry into snacks sector

  • Pratik Saraogi intends >5% stake build-up per Reg 29(1), early signal of investor interest

  • Aequs (AEPPL)(NEUTRAL-BULLISH)

    Infused ₹53.68 Cr via rights despite AEPPL losses (₹28.48 Cr FY25), using IPO proceeds for WC, 100% ownership intact

  • Aequs (ACPPL)(NEUTRAL-BULLISH)

    ₹35 Cr infusion via rights for WC despite -49% YoY turnover to ₹15.81 Cr FY25, maintaining 100% control

  • Healthcare Global (Vizag)(NEUTRAL)

    PAT ₹18.79 Cr FY25 despite -8.4% revenue to ₹110.14 Cr, acquisition at arm's length

  • Magna Electro (FETN1PL)(NEUTRAL)

    Turnover flat +1.2% YoY FY25 to ₹855.46 Lakhs post 353% surge, captive power de-risks energy costs

  • Inter-se transfer exempt under Reg 10(1)(a)(ii), no aggregate promoter change

Risk Flags(10)

  • Healthcare Global (Vizag Hospital)/Revenue Decline[HIGH RISK]

    -8.4% YoY FY25 to ₹110.14 Cr despite PAT ₹18.79 Cr, pre-acquisition weakness

  • Aequs (AEPPL)/Financial Deterioration[HIGH RISK]

    Turnover declined to ₹54.65 Cr FY25 from ₹107.6 Cr FY24 (-49%), PAT loss ₹28.48 Cr, negative net worth -₹4.36 Cr

  • Aequs (ACPPL)/Turnover Collapse[HIGH RISK]

    -49% YoY FY25 to ₹15.81 Cr from ₹31.17 Cr, PAT loss ₹12.53 Cr despite ₹242 Cr net worth

  • Magna (FETN1PL)/Growth Slowdown[MEDIUM RISK]

    Turnover +1.2% YoY FY25 to ₹855.46 Lakhs after 353% FY24 surge, indicating maturation/flat performance

  • Authum Reg 29(2) intent >5% with no stake size/value details, medium risk on execution

  • Pratik Saraogi Reg 29(1) intent >5% lacks quantitative details, low materiality but non-materialization risk

  • 9.29 Cr shares/warrants in escrow pending 26% open offer completion, execution/regulatory risks

  • Vizag acquisition related party on arm's length, funded from rights issue, completion Q1 FY27 delay risk

  • Aequs Subsidiaries/Related Party Exemption[LOW RISK]

    Investments in 100% subs not under Reg 23(5) but amid losses raises capital misallocation concerns

  • 0.37% net buy included 0.79% purchase offset by 0.42% sale, stake building but inconsistent

Opportunities(10)

  • ₹253.66 Cr total for NCHRI debt repayment + 85% Vizag stake, leverage HCG NCHRI +25.1% FY25 growth; complete Q1 FY2027

  • 1.58% stake top-up to 7.83% in FETN1PL for 1.1 MWp solar, de-risks energy costs post 353% historical growth

  • Authum >5% intent, potential takeover play in snacks amid undisclosed valuation

  • 13.42% inter-se at discount to VWAP, signals promoter conviction at 74.13% aggregate

  • BC Asia 18% FD post-warrants + 26% open offer, undervalued entry pre-public float

  • Pratik Saraogi >5% intent, alpha in small-cap finance if strategic

  • 11.72% stake post 0.37% net buy, monitor for control push

  • Aequs (AEPPL)/Turnaround Bet(OPPORTUNITY)

    ₹53.68 Cr WC infusion despite losses/decline, IPO proceeds unlock plastics growth potential

  • Aequs (ACPPL)/Consumer Recovery(OPPORTUNITY)

    ₹35 Cr for WC amid -49% drop but positive net worth ₹242 Cr, consumer products rebound play

  • Cross-Filing/Subsidiary Infusions(OPPORTUNITY)

    4/9 filings show parent investments (HCG, Aequs x2, Magna) despite mixed trends, contrarian conviction in startups

Sector Themes(6)

  • Mixed Revenue Trajectories in Investees

    5/9 filings show YoY revenue declines/deceleration (Vizag -8.4%, AEPPL -49%, ACPPL -49%, FETN1PL +1.2%); contrasts healthcare outlier +25.1%, signaling startup maturation risks but selective growth [IMPLICATION: Favor high-growth pockets like healthcare]

  • Subsidiary Capital Infusions Despite Losses

    Aequs (₹88.68 Cr total), HCG (₹253.66 Cr) pour into 100% subs amid declines/losses using IPO/rights proceeds; 3/9 filings, indicates long-term conviction over short-term returns [IMPLICATION: Watch for WC normalization catalysts]

  • Stake Acquisition Intents Clustering

    4/9 filings (Prataap, Milgrey, Sri Adhikari, BF) with >5% intents/builds/net buys; neutral sentiment but early signals in finance/snacks/media [IMPLICATION: Monitor Reg 29/PA for takeover alpha]

  • Renewables/Healthcare Outperformance

    FETN1PL +353% historical, HCG NCHRI +39.7%/+25.1%; 2/9 bullish growth vs broader declines, captive solar/health tie-ups undervalued [IMPLICATION: Sector rotation to energy/health startups]

  • Promoter/Open Offer Stability

    Manappuram 18% FD +26% offer, BF 74.13% stable post-reshuffle; no dilution risks, funded at discounts [IMPLICATION: Stable governance for funding rounds]

  • Disclosure Gaps in Early Filings

    Prataap/Milgrey Reg 29 lack details (3/9 neutral/low materiality), heightens uncertainty but precedes value unlocks [IMPLICATION: High-reward for detail trackers]

Watch List(8)

Filing Analyses(9)
Healthcare Global Enterprises LimitedMerger/Acquisitionmixedmateriality 8/10

30-03-2026

The Board of HealthCare Global Enterprises Limited approved investments of up to ₹98 Crore in wholly-owned subsidiary HCG NCHRI LLP to repay borrowings and up to ₹155.66 Crore (per Share Purchase Agreement dated June 28, 2024, as amended) for acquiring an additional 34% stake in subsidiary Vizag Hospital and Cancer Research Centre Pvt Ltd, increasing ownership to 85%. HCG NCHRI LLP demonstrated strong revenue growth from ₹51.40 Crore in FY23 to ₹71.78 Crore in FY24 (+39.7% YoY) and ₹89.80 Crore in FY25 (+25.1% YoY), with PAT of ₹17.02 Crore in FY25. However, Vizag Hospital's revenue declined to ₹110.14 Crore in FY25 from ₹120.21 Crore in FY24 (-8.4% YoY), despite PAT of ₹18.79 Crore.

  • ·HCG NCHRI LLP incorporated September 03, 2014; operates in Nagpur; no regulatory approvals required; completion expected Q1 FY2027.
  • ·Vizag Hospital incorporated March 05, 1986; registered office in Visakhapatnam, Andhra Pradesh; related party transaction on arm's length basis; investments funded from rights issue approved February 24, 2026.
  • ·Board meeting held March 30, 2026, from 01:45 p.m. to 03:40 p.m. IST.
Magna Electro Castings Ltd.Merger/Acquisitionmixedmateriality 5/10

30-03-2026

Magna Electro Castings Ltd. executed a Captive Power Agreement and Share Subscription & Shareholders Agreement with First Energy TN 1 Private Limited (FETN1PL) on March 30, 2026, investing Rs.39.60 Lakhs to acquire 3,96,000 equity shares (1.58% stake), increasing its holding from 6.25% (14,40,000 shares) to 7.83% to meet the 26% captive user shareholding requirement under the Electricity Act, 2003, for an additional 1.1 MWp solar power capacity. FETN1PL's turnover surged 353% YoY from Rs.186.32 lakhs in 2022-23 to Rs.845.27 lakhs in 2023-24; however, it grew only 1.2% YoY to Rs.855.46 lakhs in 2024-25, indicating flat recent performance.

  • ·FETN1PL CIN: U40108PN2022PTC208074; Incorporated: 29th January, 2022
  • ·FETN1PL operates in Energy Industry (Solar Power); develops captive and solar power plants on 'build own operate' basis
  • ·Acquisition not a related party transaction; no promoter/group interest
  • ·No governmental/regulatory approvals required
Prataap Snacks LimitedMerger/Acquisitionneutralmateriality 6/10

30-03-2026

BSE has received a disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 from Authum Investment & Infrastructure Ltd pertaining to Prataap Snacks Ltd (scrip: 540724). This filing indicates Authum's intention to acquire shares in Prataap Snacks that would cross or further increase a 5%+ holding threshold. No quantitative details such as stake size, transaction value, or shareholding patterns were disclosed.

BF Investment LimitedMerger/Acquisitionneutralmateriality 5/10

30-03-2026

Ajinkya Investment & Trading Company and Sundaram Trading & Investment Private Limited, promoter group members, acquired 50,54,091 equity shares (13.42% of equity share capital) of BF Investment Limited from KSL Holdings Private Limited via inter-se transfer on March 24, 2026, exempt under Regulation 10(1)(a)(ii) of SEBI (SAST) Regulations, 2011. Ajinkya's holding increased from 27.32% to 34.10%, Sundaram's from 26.00% to 32.63%, while KSL's dropped to 0%; however, aggregate promoter and promoter group shareholding remains unchanged at 27,922,726 shares (74.13%). The transaction price was approximately ₹358.20 per share, below the 60-day VWAP of ₹395.55.

  • ·Prior intimation under Reg 10(5) filed March 16, 2026
  • ·Disclosure under Reg 10(6) filed March 25, 2026
  • ·Reg 10(7) report to SEBI filed March 27, 2026
  • ·Target ISIN: INE878K01010; BSE: 533303; NSE: BFINVEST
  • ·Shareholding stable for three prior years across acquirers and seller
Manappuram Finance LimitedMerger/Acquisitionneutralmateriality 9/10

30-03-2026

Manappuram Finance Limited allotted 9,29,01,373 equity shares to BC Asia Investments XXV Limited ('Investor 1') and 9,29,01,373 warrants to BC Asia Investments XIV Limited ('Investor 2') at INR 236 each pursuant to a preferential issue approved by the Committee of Directors on March 27, 2026. This increases the total shareholding of Acquirers and Persons Acting in Concert (PACs) from 0% to 9.89% of current equity share capital (18.00% on fully diluted basis assuming warrant conversion). The allotment is held in escrow pending completion of an open offer by Investor 1 and PACs for up to 24,42,27,387 equity shares (26% of expanded voting share capital) from public shareholders.

  • ·Disclosure under Regulation 18(6) of SEBI (SAST) Regulations
  • ·Securities subscription agreement dated March 20, 2025
  • ·Public announcement issued March 20, 2025; detailed public statement March 27, 2025
  • ·Shares and warrants held in separate demat escrow accounts until open offer completion
  • ·Voting rights on allotted shares exercisable by Investor 1 post open offer
MILGREY FINANCE & INVESTMENT LTDMerger/Acquisitionneutralmateriality 3/10

30-03-2026

Milgrey Finance & Investments Ltd (BSE: 511018) has received a disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 from Pratik Saraogi, indicating intention to acquire substantial shares crossing 5% threshold or further encumbrance. No quantitative details such as transaction value, share count, percentage stake, or deal terms are disclosed in the filing. This is an early-stage regulatory prior intimation with no immediate financial metrics or impacts provided.

Sri Adhikari Brothers Television Network LimitedMerger/Acquisitionneutralmateriality 5/10

30-03-2026

Leading Leasing Finance and Investment Company Limited disclosed under SEBI Regulation 29(2) a net acquisition of 9,47,621 equity shares (0.37%) in Aqylon Nexus Limited (formerly Sri Adhikari Brothers Television Network Limited) on March 27, 2026, via open market, increasing its stake from 11.35% (2,87,89,553 shares) to 11.72% (2,97,37,174 shares). The transaction included purchase of 20,02,000 shares (0.79%) offset by sale of 10,54,379 shares (0.42%). Total equity share capital remains unchanged at 25,37,30,560 shares of Rs.1 each.

  • ·Disclosure dated March 28, 2026, submitted to BSE (Scrip Code: 530943) and NSE (Symbol: SABTNL)
  • ·Acquirer not part of promoter/promoter group
  • ·No warrants, convertible securities, or encumbrances involved
  • ·CIN of acquirer: L65910MH1983PLC016712; CIN of target: L62090MH1994PLC083853
Aequs LtdCorporate Actionmixedmateriality 7/10

30-03-2026

Aequs Limited made a further investment of INR 5,36,78,830 in its wholly owned subsidiary Aequs Engineered Plastics Private Limited (AEPPL) by subscribing to 53,67,883 equity shares at INR 10 each via rights issue, utilizing IPO proceeds for working capital needs. However, AEPPL reported a significant loss after tax of INR 28.48 Crore, negative net worth of INR -4.36 Crore, and declining turnover to INR 54.65 Crore as on March 31, 2025, down from INR 107.6 Crore in FY 2023-24 and INR 135.6 Crore in FY 2022-23. There is no change in the Company's shareholding percentage in AEPPL, which remains 100%.

  • ·AEPPL CIN: U22209KA2015PTC078777; Date of Incorporation: 10-Feb-2015
  • ·Investment is part of utilization of IPO proceeds as per Prospectus dated December 5, 2025
  • ·Transaction not classified as related party transaction under Regulation 23(5) despite AEPPL being wholly owned subsidiary
  • ·AEPPL operates in India; no governmental approvals required
Aequs LtdCorporate Actionmixedmateriality 7/10

30-03-2026

Aequs Limited invested INR 35,00,00,728 in its wholly owned subsidiary Aequs Consumer Products Private Limited (ACPPL) through a rights issue, subscribing to 24,17,800 equity shares at INR 144.76 per share, as part of IPO proceeds utilization for ACPPL's working capital requirements. ACPPL reported FY 2024-25 turnover of INR 15.81 Crore, a sharp 49% YoY decline from INR 31.17 Crore in FY 2023-24 (which was up slightly 4% from INR 29.94 Crore in FY 2022-23), coupled with a loss after tax of INR 12.53 Crore despite a networth of INR 242.12 Crore.

  • ·ACPPL incorporated on 25-Oct-2019.
  • ·ACPPL CIN: U28995KA2019PTC129087.
  • ·No change in shareholding percentage; ACPPL remains wholly owned subsidiary.
  • ·Transaction not classified as related party transaction under Reg 23(5).

Get daily alerts with 12 investment signals, 10 risk alerts, 10 opportunities and full AI analysis of all 9 filings

🇮🇳 More from India

View all →
India Startup Funding Venture Capital Filings — March 30, 2026 | Gunpowder Blog